Newsletters & Blogs

Vulnerabilities in Pharma Supply Chains

There’s no stopping Mother Nature when she gets going.

The striking force of a tornado recently tore through a Pfizer factory in Rocky Mount, N.C.  This weather event offers a poignant reminder of the intricate threads that weave their way through the pharmaceutical supply chain.

On July 19, 2023, a tornado’s rampage left the facility in a state of disarray. It’s significant because this one facility is responsible for producing major portion of crucial medications utilized in hospitals across the United States.  As a result, hospitals across the nation rushed to secure medications predominantly manufactured at the battered Pfizer site. The rush to secure supplies was exacerbated by a lack of transparency regarding which specific products were impacted and for how long shortages would persist.

The tornado’s aftermath magnified the complexity of pharmaceutical supply chains, where key information about manufacturing locations and product specifics is often obscured for regulatory purposes.

The tornado-triggered disruption mirrors other known supply chain challenges presented by extreme weather events, which are understood to be increasing as a result of global climate change. One memorable incident for the pharmaceutical industry in particular was the Hurricane Maria disaster in Puerto Rico in 2017, where an island-wide electrical and infrastructure failure at a major hub of pharmaceutical manufacturing sent shockwaves through the pharmaceutical supply chain. The hurricane disrupted production facilities, leading to shortages of crucial medications, including those used to treat chronic illnesses and life-threatening conditions. The impact of Hurricane Maria laid bare the pitfalls of over-reliance on geographically concentrated manufacturing hubs, underscoring the need for diversification to ensure continued production during crises.

Pfizer’s reported swift collaboration with wholesalers helped curb unwarranted hoarding following the Rocky Mount tornado, averting the worst outcomes of the panic-driven surges in demand. Nonetheless, the tornado’s effects draw parallels with the vulnerabilities exposed by the ongoing global COVID-19 pandemic, such as the fragile global interdependencies of pharmaceutical supply chains, which introduce fragilities across manufacturing, transportation, and international trade. The exponential spike in demand for vital medications further accentuated the urgency for adaptable supply chain strategies and judicious stockpile management. The broader message during and following the pandemic has been clear: supply chain vulnerabilities are not only susceptible to weather extremities but can also be exposed by global health emergencies.

As the pharmaceutical sector navigates these multifaceted challenges, a pivotal juncture has emerged to reevaluate and fortify supply chain preparedness. A key strategy involves diversifying manufacturing operations across various regions to minimize localized disruption risks. Collaborative engagement with regulatory bodies, along with predictive analytics, can pinpoint potential vulnerabilities and enable the proactive formulation of solutions. By confronting vulnerabilities head-on and proactively addressing them, the industry can chart a course toward a more resilient and adaptive pharmaceutical supply chain. This evolution will improve the sector’s capacity to weather not only natural disasters but also unanticipated global upheavals, securing the uninterrupted flow of critical medications to those in need.

At Crowley Law, we stand ready to guide our clients through the intricate landscape of pharmaceutical operations, including helping to negotiate protective agreements for supply chain management.  If you have concerns in this area, contact us at (908) 540-6901 to schedule a discussion with a member of our team.



About the Author

Contact Our Firm